Selegiline, also known as l-deprenyl, is an antidepressant drug used to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. It is a monoamine oxidase inhibitor (MAOI) that has been used since the late 1980s to treat depression. While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. This article will explore the potential hidden side effects of selegiline and discuss ways to uncover the unknown.
Selegiline is an MAOI that works by blocking the enzyme monoamine oxidase from breaking down certain neurotransmitters, such as dopamine and norepinephrine. This allows these neurotransmitters to remain active in the brain longer, providing a mood boost. Selegiline is generally prescribed to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease.
While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. The most common side effects of selegiline are nausea, vomiting, headache, insomnia, dry mouth, dizziness, and constipation. Other potential hidden side effects include anxiety, irritability, confusion, agitation, and hallucinations. Selegiline can also cause an increase in blood pressure and heart rate, which can be dangerous for those with pre-existing heart conditions.
Certain factors can increase the risk of experiencing hidden side effects from selegiline. These include age, gender, weight, and other medications being taken. Elderly patients are more likely to experience hidden side effects from selegiline, as they may have a lower tolerance for the drug. Women are also more likely to experience hidden side effects than men. Those who are overweight or obese may be more likely to experience hidden side effects due to the increased metabolism of the drug. Finally, those who are taking other medications may be more likely to experience hidden side effects due to potential drug interactions.
Due to the potential for hidden side effects, it is important for doctors to take steps to uncover the unknown. One way to do this is to discuss the potential side effects of selegiline with patients before they start taking the medication. It is also important to monitor patients closely while they are taking the medication, as this can help to identify any potential hidden side effects. Finally, doctors should be aware of any potential drug interactions and discuss them with patients before prescribing selegiline.
Selegiline is an effective treatment for major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. However, there are some potential hidden side effects that doctors should be aware of. By discussing the potential side effects of selegiline with patients before they start taking the medication, monitoring patients closely while they are taking the medication, and being aware of any potential drug interactions, doctors can help to uncover the unknown and ensure that patients receive the best possible care.
1.
It Is Not Just the Royals Who Go Through Cancer.
2.
Have the Harms of Lung Cancer Screening Been Exaggerated?
3.
Cancer diagnosis does not spur improvements to survivors' diets or eating habits
4.
Novel Agent for Chronic GVHD Wins FDA Approval
5.
Rising rates of head and neck cancers in England
1.
Targeted Therapy: Latest Advances, Learning Tools, Trials & Treatment Options Explained
2.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
3.
Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Hematology
2.
From Guidelines to Practice: Hematology
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
5.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation